XCUR (Exicure) ROCE %: -69.51% (As of Mar. 2026)

What is Exicure ROCE %?

Exicure XCUR -7.35% 30 ROCE % is -69.51% as of Mar. 2026. GuruFocus rates XCUR with a GF Score™ of 30/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Exicure's annualized ROCE % for the quarter that ended in Mar. 2026 was -69.51%.

Exicure (NAS:XCUR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Exicure ROCE % Related Terms

Exicure ROCE % Historical Data

* Premium members only.

The historical data trend for Exicure's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exicure ROCE % Chart

Exicure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-106.22

-6.77

-109.98

-91.90

-50.40

Exicure Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-84.10	-63.28	-73.11	-124.71	-69.51

30GF Score

Exicure Inc XCUR

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Exicure ROCE % Calculation

Exicure's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-5.579	/	( ( (15.056 - 3.071)	+	(14.041 - 3.888) )	/ 2 )
	=	-5.579	/	( (11.985	+	10.153)	/ 2 )
	=	-5.579	/	11.069
	=	-50.40 %

Exicure's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-6.412	/	( ( (14.041 - 3.888)	+	(12.755 - 4.46) )	/ 2 )
	=	-6.412	/	( ( 10.153	+	8.295 )	/ 2 )
	=	-6.412	/	9.224
	=	-69.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -69.51% mean?

Exicure (XCUR) has a ROCE % of -69.51% as of Mar. 2026.

Is Exicure's ROCE % too high?

Exicure's current ROCE % is -69.51%. Overall, Exicure has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Exicure's ROCE % compare to GRTX and AEON?

Exicure's ROCE % of -69.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Exicure's current ROCE % is -69.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Exicure stock overvalued right now?

Based on GuruFocus' analysis, Exicure (XCUR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $2.60 — trading 381.4% above its estimated fair value. The current ROCE % is -69.51%. Exicure's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Exicure (XCUR), the current ROCE % is -69.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $2.60 is trading 381.4% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

ROCE %: -69.51%
GF Value™: $0.54 vs. price of $2.60 (381.4% above fair value)
GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Industry Healthcare Biotechnology

Comparable Companies GRTX AEON ANEB NCEL PASG HOWL AKTX CRIS LPCN TRAW VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 2H0:Germany

Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063

Website https://www.exicuretx.com

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

30GF Score

Get the complete analysis for XCUR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60

Price

$0.54

GF Value

View XCUR Analysis

See ROCE % data for all stocks →